Latest Articles

Publication Date
FOSL2-driven SASP in endometrial stroma promotes the inflammation of endometriosis.

Endometriosis (EMs) is characterized by chronic pelvic inflammation, but the etiology of this inflammation remains poorly understood. The senescence-associated secretory phenotype (SASP), whereby senescent cells secrete pro-inflammatory cytokines, is a …

Published: July 24, 2026, midnight
Are We Missing the Bladder? Reflections on Endometriosis and IC/BPS.

Endometriosis and interstitial cystitis/bladder pain syndrome (IC/BPS) frequently coexist in women with chronic pelvic pain, yet overlapping symptoms and non-standardized diagnostic pathways often delay recognition of dual pathology. We propose …

Published: July 8, 2026, midnight
Investigating the effect of human amniotic membrane gel to minimize adhesions in endometriosis: findings from an experimental study using a rat model.

Postoperative adhesions and inflammation remain major challenges following endometriosis surgery. Human amniotic membrane gel (HAG) has emerged as a potential therapeutic strategy with both anti-adhesive and anti-inflammatory properties. This study …

Published: July 8, 2026, midnight
Ceramide: a pivotal lipid mediator shaping female reproductive homeostasis and pathophysiology.

Ceramide, a central hub in sphingolipid metabolism, serves as a critical bioactive signalling mediator that integrates lipid metabolism with multiple signalling pathways, primarily promoting autophagy and apoptosis. It influences female …

Published: June 15, 2026, midnight
Anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for Alpelisib delivery regulate Sema3A-NRP1/PI3K-AKT signaling to balance oxidative stress and inhibit angiogenesis in endometriosis.

Endometriosis progression is driven by oxidative stress and excessive angiogenesis within an inflammatory microenvironment. To overcome these challenges, we designed ROS/pH dual-responsive Alpelisib-loaded nanoparticles (Alp@TAT-AT7-NPs) functionalized with an anti-NRP1 peptide …

Published: June 6, 2026, midnight
SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.

Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality among children and young adults, particularly in low- and middle-income countries. Current management relies on antibiotic …

Published: June 4, 2026, midnight
Resveratrol alleviates endometriosis via restoration of hypoxic milieu and inhibition of autoantibody deposition.

Endometriosis, a chronic disease that affects about 10% of women of reproductive age, is characterized by severe pain and growth of endometrium-like tissues outside the uteri. Although several theories have …

Published: May 9, 2026, midnight
Microecological modulators-new perspectives for treating sex hormone disorders.

Sex hormone related disorders, characterized by complex etiology and long-term health risks, pose a significant challenge to global health. Hormone-based therapies are often accompanied by adverse effects and fail to …

Published: April 30, 2026, midnight
Clinically Validated Leptin Receptor as a Target for Liposomal Delivery of Metformin in Endometriosis Therapy.

Endometriosis is a common, estrogen-driven chronic gynecologic disorder defined by the ectopic growth of endometrial-like tissue within the peritoneal cavity. Existing treatment options, primarily surgery and hormonal therapy, are limited …

Published: April 29, 2026, midnight
Pelargonium graveolens Essential Oil Suppresses Proliferation and Migration and Modulates Mesenchymal-Associated Cellular Functions in Human Endometriotic Cells.

Endometriosis is characterized by enhanced cellular proliferation, migration, and resistance to apoptosis, contributing to lesion persistence and progression. Targeting cellular plasticity and mesenchymal-associated functions may therefore represent a promising therapeutic …

Published: April 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!